Floatz logo

Tocilizumab

Locally Advanced Renal Pelvis Urothelial Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Locally Advanced Renal Pelvis Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
MITOMYCIN C
UroGen Pharma Ltd.
Phase 3B
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B

View all 22 →

Same molecule, other indications

Tocilizumab is also rated in:

rheumatoid arthritisDormant
BB
Indicative ·
66 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
65 / 100
View asset →
acute chest syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →